ARTICLE | Distillery Therapeutics

Therapeutics: CD47

June 30, 2016 7:00 AM UTC

Patient sample, cell culture and mouse studies suggest Hu5F9-G4, a mAb against CD47, could help treat small cell lung cancer. In patient tumor samples, CD47 was highly expressed. In co-cultures of primary human macrophages and human small cell lung cancer cell lines, Hu5F9-G4 increased macrophage phagocytosis of tumor cells compared with vehicle. In patient-derived xenograft and orthotopic xenograft mouse models of small cell lung cancer, Hu5F9-G4 decreased tumor growth and increased tumor infiltration by macrophages and survival. Next steps could include testing the antibody in small cell lung cancer patients.

Forty Seven Inc. and Stanford University have Hu5F9-G4 in Phase I testing to treat acute myelogenous leukemia (AML) and solid tumors...